Pharmaceutical companies have stepped up pressure on the Government to push back against proposed new regulations of the sector, which pharma giant Pfizer privately warned could damage the Irish ...

The FDA plans to limit access to certain high-risk groups and also told Pfizer and Moderna to update their warning labels ...

Pfizer plans to advance its R&D pipeline ... driven by reduced Paxlovid sales and changes in Medicare policies. Operating expense reductions accelerated in Q1 2025 compared to Q4 2024, aligning ...

Global pharmaceutical company Pfizer (NYSE:PFE) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling ...

Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...

Despite a 6% revenue drop, Pfizer Inc (PFE) focuses on R&D advancements, cost savings, and dividend growth to drive future success.

Last week Pfizer announced that Ian Read is to step down as CEO, with chief operating officer Albert Bourla taking the helm. Following the change of leadership, Pfizer is also revamping its ...

The company also reaffirmed its guidance for the remainder of the year, emphasizing its strategic focus on research and development along with operational efficiencies. Pfizer reported revenues of $13 ...

Pfizer Inc. PFE will release earnings results ... Readers can sort by stock ticker, company name, analyst firm, rating change or other variables. Let's have a look at how Benzinga's most-accurate ...